About Stage III NSCLC

Testing

Stage III NSCLC is a heterogeneous disease1

Approximately one-fifth of patients with NSCLC present with Stage III disease, and the majority have unresectable tumours2

In Stage III NSCLC, cure is the treatment goal1

img-30
img-30
 - Patients with NSCLC who present with Stage III disease2

THE IASLC STAGING MANUAL IN THORACIC ONCOLOGY, VERSION 8 SUBDIVIDES STAGE III NSCLC INTO IIIA, IIIB AND IIIC PRESENTATIONS3

Testing

NSCLC: Non-Small Cell Lung Cancer; IASLC: International Association for the Study of Lung Cancer;

Which of your patients could
benefit from IMFINZI?

SEE SUPPORTING MATERIALS
patients_profile
patients_profile
posology
posology

NEXT
IMFINZI helps restore the anti-tumour immune response8

SEE IMFINZI IN ACTION

References: 1. Eberhardt W..E , De Ruysscher D, Weder W, et al; 2nd ESMO Consensus Conference in Lung Cancer:locally advanced stage III non-small-cell lung cancer Ann Oncol. 2015;26:1573-1588. 2. Royal College of Physicians UK. National Lung Cancer Audit Annual report 2018. https://www.rcplondon.ac.uk/projects/national-lung-cancer-audit. (Accessed June 2020) 3. Detterbeck FC, Boffa. DJ, Kim. AW, et al; The Eighth Edition Lung Cancer Stage Classification Chest. 2017;151(1):193-203. 4. Postmus PE, Kerr KM, Oudkerk M, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. 5. Curran WJ Jr, Paulus R, Langer CJ, et al; Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst. 2011;103(9):1452-1460. 6. Hanna N, Neubauer M, Yiannoutsos C, et al; Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol. 2008;26(35):5755-5760. 7. Auperin A, Pechoux. CL, Rolland. E, et al. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer J Clin Oncol. 2010;28(13):2181-2190. 8. Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015;3(9):1052-1062.